OGT

It’s time for another edition of OGT’s publications in focus! Discover how CytoCell® FISH, SureSeq™ NGS and CytoSure® array products are being used in recent papers and articles* from our customers and partners in the field. 🔬 “Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a non-productive KMT2A rearrangement in B-ALL” During the study conventional chromosome analysis was performed using standard cytogenetic techniques on white blood cells from the bone marrow aspirate, which included utilisation of CytoCell CRLF2 Breakapart and P2RY8 Deletion FISH probes. View publication: https://lnkd.in/eUBBdNgj 🔬 “Identification and characterization of stromal-like cells with CD207+/low CD1a+/low phenotype derived from histiocytic lesions – a perspective in vitro model for drug testing” aCGH was performed using the 60k CytoSure Constitutional v3 microarray. CytoSure Interpret Software was used for monitoring of quality control measures, data analysis and CNV classification. View publication: https://lnkd.in/euv4kQ9n 🔬 “Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes” Various FISH probes were used in this study, including CytoCell IGK Breakapart and IGL Breakapart. View publication: https://lnkd.in/eYpKhKWu #CytoCell #SureSeq #CytoSure *Providing links to these publications is intended for educational purposes only and does not replace independent professional judgement. Statements of fact and opinions expressed are those of the publications’ authors and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented in these publications.

📢Calling all NGS users📢 At OGT, we are committed to delivering on all your lab's research needs! Your insights are invaluable in shaping the future of scientific innovation and we are here to listen. Today, we’re talking about automation systems for NGS libraries. These systems can prove to be helpful for streamlining your NGS workflows, reducing hands-on time and increasing reproducibility in your NGS library preparation. #TellOGT

In this month’s edition of OGT’s publications in focus, learn about how CytoCell® FISH, SureSeq™ NGS and CytoSure® array products are being used in the latest papers and articles* from our customers and partners in the field. 🔬 “BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases” (This study utilised CytoCell break-apart probes for TCF3::PBX1, CRFL2, JAK2, EPOR, ABL1, ABL2 and, additionally, for IGH and P2RY8 in the CRLF2 rearranged (CRLF2-r) cases) View publication: https://lnkd.in/eRfTzGMa 🔬 “PTPN11 mosaicism causes a spectrum of pigmentary and vascular neurocutaneous disorders and predisposes to melanoma” (Affected skin DNA was sequenced on a targeted next-generation sequencing panel using a SureSeq custom panel of 250 candidate genes of interest) View publication: https://lnkd.in/em9xv8ur 🔬 “17q21.31 microduplication syndrome in a patient with autism spectrum disorder, macrocephaly, and intellectual disability” (During this study aCGH was performed using the CytoSure ISCA 8 × 60K v.2) View publication: https://lnkd.in/e4niCFVU * Providing links to these publications is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the publications’ authors and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented in these publications.

Sign up for an exclusive seminar on the healthcare journey in AML. Join our parent company, Sysmex Europe Life Science, as they bring you an insightful seminar on Acute Myeloid Leukemia (AML), featuring the distinguished speaker, Prof. Klaus Metzeler, a leading Physician-scientist in the field of haematological malignancies. Don’t miss this opportunity to gain a deeper understanding of the healthcare journey in AML, from diagnosis through treatment and recovery.

Today is World Acute Lymphoblastic Leukaemia Day, and all of us at OGT believe in the importance of spreading awareness about this complex disease. Acute lymphoblastic (or lymphocytic) leukaemia (ALL) is a rapidly progressing cancer that primarily affects children and older adults. Early and accurate diagnosis is vital, as it develops quickly over the course of days or weeks. Below we have provided some key statistics and symptoms of ALL.* Together, we can increase awareness of ALL and work towards a future where every patient has access to the best possible care. To learn more about World Acute Lymphoblastic Leukaemia Day and how you can get involved visit the Know ALL website: https://lnkd.in/eKGuVYVX #WorldALLDay *Statistics and symptoms taken from the American Cancer Society website: https://lnkd.in/eK_d4r_h

At OGT, we’re committed to furthering the understanding of haematological malignancies and our bi-monthly haematological cancer quizzes are a great way to keep your knowledge sharp! This month the focus is on lymphoma, a type of cancer that affects the lymphatic system, a key part of the body's immune system. The lymphatic system includes lymph nodes, lymphatic vessels, the thymus, the spleen, and bone marrow. Ready to put your lymphoma knowledge to the test? Try our quiz: https://lnkd.in/eFdyQTFA #OGTestYourKnowledge #Lymphoma

#ESMO2024 is well underway! If you are here be sure to stop by booth #504, which we are sharing with our parent company Sysmex Europe. Our team of OGT experts will be delighted to have a chat with you about how our haematological range of FISH, array and NGS products can help your lab.

OGT supports World Lymphoma Awareness Day and its mission to raise awareness of lymphoma. Lymphoma is a complex cancer that affects the lymphatic system, developing when white blood cells called lymphocytes grow abnormally and are unable to work properly. There are two primary types of lymphoma: 1. Hodgkin lymphoma 2. Non-Hodgkin lymphoma Sadly, there are still thousands of new cases and disease-related deaths every year. Statistics for 2024 are shown below*. To learn more about World Lymphoma Day and how you can get involved visit the Lymphoma Coalition website: https://lnkd.in/eKZYsRn4 #WorldLymphomaAwarenessDay #WLAD24 #LetsTalkLymphoma *Source: American Cancer Society: https://lnkd.in/e3-qjpiD

Today – 12th September – everyone at OGT would like to voice their support for MPN Awareness Day and its mission to raise awareness about myeloproliferative neoplasms (MPNs). MPNs are a group of rare blood cancers that affect the bone marrow and the production of different blood cells. Early detection and ongoing monitoring is crucial for managing MPNs and improving patient outcomes. For more information about how to get involved in MPN Awareness Day you can visit the Voices of MPN website: https://lnkd.in/eijkyuMC #MPNAwarenessDay #BloodCancerAwarenessMonth

A big thank-you to everyone who came to meet us at Genética 2024 in Brazil 🇧🇷! OGT’s own Dave Bohanna and Graham Halford joined Molecular Biotecnologia to share their FISH expertise with cytogeneticists and clinical scientists from across the country. There were lots of great conversations, and some fantastic speeches from clinicians and academics from around the world! #CytoCell #Genética2024